The artificial liver support system (ALSS) in patients with acute on chronic liver failure - the use of combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE), its effect on primary coagulation, inflammation and the function of vital organs.
Adult patient, age ≥18 years
Expressed consent to the inclusion
Patient hospitalized on ICU with ALF or ACLF diagnosis
Recently meeting the inclusion to liver transplantation
Disagreement with the study
Infaust prognosis with expected survival less than 24 hours
Physiologically/biologically very advanced stage patients condition, severe lung disease (Gold criteria 3 or 4), heart failure (functional class NYHA III or IV) or neurological disease, as well as ACLF-3.
Advanced oncological disease (expected life expectancy below 6 months)